Although drug development and clinical trials for stroke have never stopped and many potential stroke therapeutic targets and potential drugs have been identified (see table below), no effective treatment or prevention of stroke has been established, and progress in targeted drug research has been unsatisfactory. In addition, the blood-brain barrier is a major challenge impeding stroke drug development. The only widely used stroke therapy is reperfusion with recombinant tissue plasminogen activator (rtPA), but due to contraindications, only about 10% of patients can receive this therapy. The more research directions there are, the better the chances of successful stroke therapy development. Source from:

Danke für den Blog, der mit solch riesigen Daten vollgestopft ist. Der Besuch Ihres Blogs hat mir geholfen, das zu finden, wonach ich gesucht habe.